The UK’s national healthcare provider saved £324 million by switching its patients to “better value” biosimilar and generic drugs, which are considered to be “equally effective alternatives
Novelion Therapeutics’ Myalepta (metreleptin) developed for the ultra-rare condition lipodystrophy has been approved by the European Commission, giving patients the first treatment to impro
European Commission (EC) has approved Pfizer’s Trazimera, for breast and gastric cancer treatment, marking it as pharma’s first oncology biosimilar to receive approval in the EU.
Danish LEO Pharma announced yesterday (July 31st) that it has entered a binding agreement to purchase Bayer's global prescription dermatology portfolio, in line with its goal to help 125 mi
Orphan drugs for cystic fibrosis and the hereditary rare disease hATTR are on course for European approval after winning the backing of a key regulatory advisory committee.
